# Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

> **NCT03768570** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Canadian Cancer Trials Group** · enrollment: 82 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT03768570
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-25
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2026-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03768570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03768570, "Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03768570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*